Gamma-probe-directed lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma

被引:5
作者
Belhocine, T
Piérard, GE
Gielen, JL
Daenen, F
De Barsy, C
Arrese, JE
Lahaye, T
Rigo, P
机构
[1] Univ Liege, Div Nucl Med, B-4000 Liege, Belgium
[2] Univ Liege, Dept Dermatopathol, B-4000 Liege, Belgium
[3] Univ Liege, Dept Plast Surg, B-4000 Liege, Belgium
关键词
malignant melanoma; sentinel lymph node; lymphatic mapping; gamma probe;
D O I
10.1159/000063385
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Radiotracer and blue-dye lymphatic mapping is a recommended combined method to guide sentinel lymphadenectomy and full regional lymph node dissection in selected patients with cutaneous melanoma. Objective: To evaluate the diagnostic accuracy and the prognostic value of gamma-probe-directed lymphatic mapping in cutaneous melanomas. Methods: Sixty-five stage I and 11 melanoma patients underwent gamma-probe-directed lymphatic mapping. Sentinel lymph nodes were studied by both conventional and immunohistochemical stainings. The median follow-up was 11 months. Results: Sensitivities of preoperative and intraoperative sentinel lymph node detection were 100 and 98%, respectively. Only 1 failure of detection and 1 missed same-basin metastasis were experienced in the axillary and cervical areas, respectively. Eleven patients (16.9%) had sentinel node metastases leading to adjuvant therapy. Conclusion: Gamma-probe-directed lymphatic mapping is useful for staging melanoma. However, in the expectation of a more specific identification of the sentinel lymph node, the standard protocol remains recommended for exploring the axillary and cervical areas. The histological examination supported in some cases by immunohistochemistry remains mandatory in all cases. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:355 / 361
页数:7
相关论文
共 35 条
[1]   Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma [J].
Albertini, JJ ;
Cruse, CW ;
Rapaport, D ;
Wells, K ;
Ross, M ;
DeConti, R ;
Berman, CG ;
Jared, K ;
Messina, J ;
Lyman, G ;
Glass, F ;
Fenske, N ;
Reintgen, DS .
ANNALS OF SURGERY, 1996, 223 (02) :217-224
[2]   GAMMA-PROBE-GUIDED LYMPH-NODE LOCALIZATION IN MALIGNANT-MELANOMA [J].
ALEX, JC ;
WEAVER, DL ;
FAIRBANK, JT ;
RANKIN, BS ;
KRAG, DN .
SURGICAL ONCOLOGY-OXFORD, 1993, 2 (05) :303-308
[4]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[5]   Towards quality assurance of the sentinel node procedure in malignant melanoma patients: a single institution evaluation and a European survey [J].
Bongers, V ;
Rinkes, IHMB ;
Barneveld, PC ;
Canninga-van Dijk, MR ;
van Rijk, PP ;
van Vloten, WA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (02) :84-90
[6]   Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas [J].
Cherpelis, BS ;
Haddad, F ;
Messina, J ;
Cantor, AB ;
Fitzmorris, K ;
Reintgen, DS ;
Fenske, NA ;
Glass, LF .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (05) :762-766
[7]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[8]  
Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO
[9]  
2-0
[10]   Outcome of patients with melanoma and histologically negative sentinel lymph nodes [J].
Gadd, MA ;
Cosimi, AB ;
Yu, J ;
Duncan, LM ;
Yu, L ;
Flotte, TJ ;
Souba, WW ;
Ott, MJ ;
Wong, LS ;
Sober, AJ ;
Mihm, MC ;
Haluska, FG ;
Tanabe, KK .
ARCHIVES OF SURGERY, 1999, 134 (04) :381-387